Universal exposure (HSV-1 60-90% adults; HSV-2 ~ 12%); lifetime latency in sensory ganglia; recurrence + reactivation common; encephalitis = neuro emergency; acyclovir/valacyclovir mainstay; new chronic suppression + pritelivir + emerging vaccines。